Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.
Press releases published on August 26, 2025
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Voyager to Present at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following …
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 26, 2025
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management …
Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p. …
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
GlobeNewswire
·
August 26, 2025
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming …
Breaking the Sick Cycle: How Healthletic's First-Day Colostrum With 25% IgG Is Revolutionizing Natural Immune Defense
GlobeNewswire
·
August 26, 2025
New York, USA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- In an era where the average adult loses 5-7 work days annually to illness and parents navigate an endless cycle of daycare bugs, a growing body of research points to bovine colostrum—specifically first-day …
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
GlobeNewswire
·
August 26, 2025
Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …
Scenic Enters License and Research Agreement with Alnylam
GlobeNewswire
·
August 26, 2025
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform …
Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey
GlobeNewswire
·
August 26, 2025
WARSAW, Poland and LONDON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement with CNX Therapeutics to supply selected …
Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases
GlobeNewswire
·
August 26, 2025
ER-300 improves key biomarkers of liver health in an animal model of MASH These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear restoration of methylation patterns with functional enrichment of …
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
GlobeNewswire
·
August 26, 2025
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that …
CancerVax Achieves Major Milestones and Files Foundational Patent Application
GlobeNewswire
·
August 26, 2025
Lehi, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 26, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that it recently filed a …
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline
GlobeNewswire
·
August 26, 2025
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission file completed with French regulatory agency (ANSM) to …
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire
GlobeNewswire
·
August 26, 2025
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire Dossier de pré-soumission finalisé auprès de l'Agence …
PathAI Expands AISight® Dx Primary Diagnosis Clearance to Support VENTANA DP 200 and DP 600 Slide Scanners Through Predetermined Change Control Plan (PCCP)
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the expansion of the AISight® Dx digital pathology image management system 510(k) label (K243391) to include …
Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
GlobeNewswire
·
August 26, 2025
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics Initiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 in Extensive stage small cell lung cancer ( …
Nicox Announces Shareholder Q&A Webpage Available
GlobeNewswire
·
August 26, 2025
Press Release Nicox Announces Shareholder Q…
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet
GlobeNewswire
·
August 26, 2025
Communiqué de presse Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet 26 août 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société …
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
GlobeNewswire
·
August 26, 2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office …